Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-25-110393
Filing Date
2025-11-12
Accepted
2025-11-12 16:16:53
Documents
66
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q anvs-20250930x10q.htm   iXBRL 10-Q 1230462
2 EX-31.1 anvs-20250930xex31d1.htm EX-31.1 12674
3 EX-31.2 anvs-20250930xex31d2.htm EX-31.2 12726
4 EX-32.1 anvs-20250930xex32d1.htm EX-32.1 7918
  Complete submission text file 0001104659-25-110393.txt   6111743

Data Files

Seq Description Document Type Size
5 EX-101.SCH anvs-20250930.xsd EX-101.SCH 46586
6 EX-101.CAL anvs-20250930_cal.xml EX-101.CAL 32493
7 EX-101.DEF anvs-20250930_def.xml EX-101.DEF 154502
8 EX-101.LAB anvs-20250930_lab.xml EX-101.LAB 376096
9 EX-101.PRE anvs-20250930_pre.xml EX-101.PRE 284658
69 EXTRACTED XBRL INSTANCE DOCUMENT anvs-20250930x10q_htm.xml XML 1107979
Mailing Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39202 | Film No.: 251472994
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)